Cancer Letters
Volume 241, Issue 1 , Pages 69-78 , 8 September 2006

The synthetic epoxyquinoids jesterone dimer and epoxyquinone A monomer induce apoptosis and inhibit REL (human c-Rel) DNA binding in an IκBα-deficient diffuse large B-cell lymphoma cell line

  • Mei-Chih Liang

      Affiliations

    • Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
    • ,
  • Sujata Bardhan

      Affiliations

    • Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA
    • Center for Chemical Methodology and Library Development, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA
    • ,
  • John A. Porco Jr.

      Affiliations

    • Department of Chemistry, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA
    • Center for Chemical Methodology and Library Development, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA
    • ,
  • Thomas D. Gilmore

      Affiliations

    • Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA
    • Center for Chemical Methodology and Library Development, Boston University, 590 Commonwealth Avenue, Boston, MA 02215, USA
    • Corresponding Author InformationCorresponding author. Address: Department of Biology, Boston University, 5 Cummington Street, Boston, MA 02215, USA. Tel.: +1 617 353 5444; fax: +1 617 353 6340.

Received 16 August 2005 ,Accepted 7 October 2005.

References 

  1. Loop T, Pahl HL. Activators and target genes of Rel/NF-κB transcription factors. In:  Beyaert R editors. Nuclear Factor κB: Regulation and Role in Disease. Amsterdam: Kluwer Academic Publishers; 2003;p. 1–48
  2. Hayden MS, Ghosh S. Signaling to NF-κB. Genes Dev. 2004;18:2195–2224
  3. Tak PP, Firestein GS. NF-κB: a key role in inflammatory disease. J. Clin. Invest. 2001;107:7–11
  4. Gilmore TD, Gapuzan M-E, Kalaitzidis D, Starczynowski D. Rel/NF-κB/IκB signal transduction in the generation and treatment of human cancer. Cancer Lett. 2002;181:1–9
  5. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: its role in health and disease. J. Mol. Med. 2004;82:434–448
  6. Gilmore TD, Kalaitzidis D, Liang M-C, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene. 2004;23:2275–2286
  7. Wood KM, Roff M, Hay RT. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene. 1998;16:2131–2139
  8. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene. 1999;18:3063–3070
  9. Emmerich F, Meiser M, Hummel M, Demel G, Foss H-D, Jundt F, et al. Overexpression of IκBα without inhibition of NF-κB activity and mutations in the IκBα gene in Reed–Sternberg cells. Blood. 1999;94:3129–3134
  10. Jungnickel B, Staratschek-Jox A, Bräuninger A, Spieker T, Wolf J, Diehl V, et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's lymphoma. J. Exp. Med. 2000;191:395–402
  11. Mathas S, Lietz A, Janz M, Hinz M, Jundt F, Scheidereit C, et al. Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis. Blood. 2003;102:1028–1034
  12. Kalaitzidis D, Davis RE, Rosenwald A, Staudt LM, Gilmore TD. The human B-cell lymphoma cell line RC-K8 has multiple genetic alterations that dysregulate the Rel/NF-κB signal transduction pathway. Oncogene. 2002;21:8759–8768
  13. Kwok BHB, Koh B, Ndubuisi MI, Elofsson M, Crews CM. The anti-inflammatory natural product parthenolide from the medicinal herb Feverfew directly binds to and inhibits IκB kinase. Chem. Biol. 2001;8:759–766
  14. Haridas V, Arntzen CJ, Gutterman JU. Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), inhibit activation of nuclear factor-κB by inhibiting both its nuclear localization and ability to bind DNA. Proc. Natl Acad. Sci. USA. 2001;98:11557–11562
  15. Ojo-Amaize EA, Kapahi P, Kakkanaiah VN, Takahashi T, Shalom-Barak T, Cottam HB, et al. Hypoestoxide, a novel anti-inflammatory natural diterpene, inhibits the activity of IκB kinase. Cell. Immunol. 2001;209:149–157
  16. Yang F, Oz HS, Barve S, de Villiers WJS, McClain CJ, Varilek GW. The green tea polyphenol (–)-epigallocatechin-3-gallate blocks nuclear factor-κB activation by inhibiting IκB kinase activity in the intestinal epithelial cell line IEC-6. Mol. Pharmacol. 2001;60:528–533
  17. Cárcamo JM, Pedraza A, Bórquez-Ojeda O, Zhang B, Sanchez R, Golde DW. Vitamin C is a kinase inhibitor: dehydroascorbic acid inhibits IκBα kinase β. Mol. Cell. Biol. 2004;24:6645–6652
  18. Ariga A, Namekawa J, Matsumoto N, Inoue J, Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 2002;277:24625–24630
  19. Liang M-C, Bardhan S, Li C, Pace EA, Porco JA, Gilmore TD. Jesterone dimer, a synthetic derivative of the fungal metabolite jesterone, blocks activation of transcription factor nuclear factor κB by inhibiting the inhibitor of κB kinase. Mol. Pharmacol. 2003;64:123–131
  20. Li C, Bardhan S, Pace EA, Liang M-C, Gilmore TD, Porco JA. Angiogenesis inhibitor epoxyquinol A: total synthesis and inhibition of transcription factor NF-κB. Org. Lett. 2002;4:3267–3270
  21. M.-C. Liang, S. Bardhan, E.A. Pace, D. Rosman, J.A. Beutler, J.A. Porco Jr., et al., Inhibition of transcription factor NF-κB signaling proteins IKKβ and p65 through specific cysteine residues by epoxyquinone A monomer: correlation with its anti-cancer cell growth activity, Biochem. Pharmacol., in press.
  22. Hu Y, Li C, Kulkarni BA, Strobel G, Lobkovsky E, Torczynski RM, et al. Exploring chemical diversity of epoxyquinoid natural products: synthesis and biological activity of (–)-jesterone and related molecules. Org. Lett. 2001;3:1649–1652
  23. Kikuchi E, Horiguchi Y, Nakashima J, Kuroda K, Oya M, Ohigashi T, et al. Suppression of hormone-refractory prostate cancer by a novel nuclear factor κB inhibitor in nude mice. Cancer Res. 2003;63:107–110
  24. Starenki DV, Namba H, Saenko VA, Ohtsuru A, Maeda S, Umezawa K, et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 2004;10:6821–6829
  25. Matsumoto N, Ariga A, To-e S, Nakamura H, Agata N, Hirano S-i, et al. Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 2000;10:865–869
  26. Watanabe M, Dewan MZ, Okamura T, Sasaki M, Itoh K, Higashihara M, et al. A novel NF-κB inhibitor DHMEQ selectively targets constitutive NF-κB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo. Int. J. Cancer. 2005;114:32–38
  27. Ohsugi T, Hone R, Kumasaka T, Ishida A, Ishida T, Yamaguchi K, et al. In vivo antitumor activity of the NF-κB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis. 2005;26:1382–1388
  28. Barkett M, Dooher JE, Lemonnier L, Simmons L, Scarpati JN, Wang Y, et al. Three mutations in v-Rel render it resistant to cleavage by cell-death protease caspase-3. Biochim. Biophys. Acta. 2001;1526:25–36
  29. Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer. 2002;34:129–135
  30. Shirra MK, Hansen U. LSF and NTF-1 share a conserved DNA recognition motif yet require different oligomerization states to form a stable protein–DNA complex. J. Biol. Chem. 1998;273:19260–19268
  31. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001;194:1861–1874
  32. Glineur C, Davioud-Charvet E, Vandenbunder B. The conserved redox-sensitive cysteine residue of the DNA-binding region in the c-Rel protein is involved in the regulation of the phosphorylation of the protein. Biochem. J. 2000;352:583–591
  33. García-Piñeres AJ, Castro V, Mora G, Schmidt TJ, Strunck E, Pahl HL, et al. Cysteine 38 in p65/NF-κB plays a crucial role in DNA binding inhibition by sesquiterpene lactones. J. Biol. Chem. 2001;276:39713–39720
  34. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang C-H, et al. 15-deoxy-Δ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway. Proc. Natl Acad. Sci. USA. 2000;97:4844–4849
  35. Cernuda-Morollón E, Pineda-Molina E, Cañada FJ, Pérez-Sala D. 15-Deoxy-Δ12,14-prostaglandin J2 inhibition of NF-κB-DNA binding through covalent modification of the p50 subunit. J. Biol. Chem. 2001;276:35530–35536
  36. Lee JH, Koo TH, Hwang BY, Lee JJ. Kaurane diterpene, kamebakaurin, inhibits NF-κB by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. J. Biol. Chem. 2002;277:18411–18420
  37. Xia YF, Ye BQ, Li YD, Wang JG, He XJ, Lin X, et al. Andrographolide attenuates inflammation by inhibition of NF-κB activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 2004;173:4207–4217
  38. Park MH, Song HS, Kim KH, Son DJ, Lee SH, Yoon DY, et al. Cobrotoxin inhibits NF-κB activation and target gene expression through reaction with NF-κB signal molecules. Biochemistry. 2005;44:8326–8336
  39. Matthews JR, Wakasugu N, Virelizier J-L, Yodoi J, Hay RT. Thioredoxin regulates the DNA binding activity of NF-κB by reduction of a disulfide bond involving cysteine 62. Nucleic Acids Res. 1992;20:3821–3830
  40. Ghosh G, Duyne GV, Ghosh S, Sigler PB. Structure of NF-κB homodimer bound to a κB site. Nature. 1995;373:303–310
  41. Chen YQ, Ghosh S, Ghosh G. A novel recognition mode by the NF-κB p65 homodimer. Nat–Struct. Biol. 1998;5:67–73
  42. Huang D-B, Chen Y-Q, Ruetsche M, Phelps CB, Ghosh G. X-ray crystal structure of proto-oncogene product c-Rel bound to the CD28 response element of IL-2. Structure. 2001;9:669–678
  43. Tatetsu H, Okuno Y, Nakamura M, Matsuno F, Sonoki T, Taniguchi I, et al. Dehydroxymethylepoxyquinomicin, a novel nuclear factor-κB inhibitor, induces apoptosis in multiple myeloma cells in an IκBα-independent manner. Mol. Cancer Ther. 2005;4:1114–1120

PII: S0304-3835(05)00912-2

doi: 10.1016/j.canlet.2005.10.004

Cancer Letters
Volume 241, Issue 1 , Pages 69-78 , 8 September 2006

Article Tools

* Image Usage & Resolution